ZymoGenetics has restructured of the U.S. co-promotion and ex-U.S. license and collaboration agreements with Bayer Schering Pharma AG and Bayer HealthCare relating to Recothrom Thrombin, topical (Recombinant). Effective January 1, 2010, ZymoGenetics regains full promotion rights in the U.S. and all ex-U.S. rights except in Canada, where Bayer will market and sell the product. “The amended agreements with Bayer should benefit ZymoGenetics in a number of ways,” said Douglas E. Williams, Ph.D., ...